NCT02711007View on ClinicalTrials.gov

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 30, 2017

Study Completion Date

January 8, 2018

Conditions
OsteosarcomaMetastasis
Interventions
DRUG

apatinib

Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

GUO WEI

OTHER

NCT02711007 - Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy | Biotech Hunter | Biotech Hunter